

16 January 2026

## **Osteopore strikes exclusive collaboration with Majeton to access the Chinese market**

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – would like to provide clarification details relating to its definitive agreement with Majeton for the commercialisation of its innovative dental, orthodontic, and maxillofacial products in China, Hong Kong, and Macau.

The agreement is effective from 15 January 2026 and will continue unless terminated by giving 12 months prior written notice or in accordance with customary termination clauses.

The agreement has the following payments and regulatory milestones:

RMB 2.5m upfront dossier fee

RMB 1m upon obtaining regulatory approval in Macau

RMB 1m upon acceptance of clinical trial submission to the regulatory authority in China

RMB 3m upon obtaining regulatory approval in China

RMB 2m for 50,000 units sold in the Greater Bay Area

RMB 2.5m for 100,000 (additional) sold in mainland China

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

**Lim Yujing**

Chief Executive Officer

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Mark Leong**

Executive Chairman

Osteopore Limited

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

**About Osteopore Limited**

Osteopore Limited is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

**Forward-Looking Statements**

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates, and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

## ASX ANNOUNCEMENT

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of the information, opinions, or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's directors, employees, advisors, or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement.

The forward-looking statements in this announcement reflect views held only as of the date of this announcement. This announcement is not an offer, invitation, or recommendation to subscribe for or purchase securities by the Company, nor does this announcement constitute investment or financial product advice (nor tax, accounting, or legal advice), and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.